 Julie Goddard
Concepts (152)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Head and Neck Neoplasms | 7 | 2023 | 427 | 1.160 |
Why?
| | Free Tissue Flaps | 4 | 2023 | 32 | 1.090 |
Why?
| | Otolaryngologists | 1 | 2018 | 10 | 0.620 |
Why?
| | Carcinoma, Squamous Cell | 6 | 2019 | 577 | 0.600 |
Why?
| | Microsurgery | 1 | 2018 | 59 | 0.600 |
Why?
| | Parotitis | 1 | 2017 | 6 | 0.570 |
Why?
| | Parotid Gland | 1 | 2017 | 24 | 0.570 |
Why?
| | Antibiotic Prophylaxis | 1 | 2017 | 96 | 0.550 |
Why?
| | Vascular Malformations | 1 | 2017 | 47 | 0.540 |
Why?
| | Surgical Wound Infection | 1 | 2017 | 248 | 0.480 |
Why?
| | Lymph Node Excision | 2 | 2019 | 139 | 0.440 |
Why?
| | Neoplasm Recurrence, Local | 3 | 2020 | 858 | 0.440 |
Why?
| | Thyroidectomy | 1 | 2013 | 53 | 0.430 |
Why?
| | Carcinoma | 1 | 2013 | 198 | 0.380 |
Why?
| | Practice Patterns, Physicians' | 1 | 2018 | 1177 | 0.350 |
Why?
| | Thyroid Neoplasms | 1 | 2013 | 264 | 0.340 |
Why?
| | Eyelids | 1 | 2022 | 29 | 0.200 |
Why?
| | Orbit | 1 | 2022 | 59 | 0.190 |
Why?
| | Laryngectomy | 2 | 2018 | 13 | 0.190 |
Why?
| | Margins of Excision | 2 | 2018 | 29 | 0.190 |
Why?
| | Lymphatic Metastasis | 2 | 2019 | 275 | 0.180 |
Why?
| | Laryngeal Neoplasms | 2 | 2020 | 27 | 0.180 |
Why?
| | Oropharynx | 1 | 2020 | 36 | 0.180 |
Why?
| | Mouth | 1 | 2020 | 70 | 0.180 |
Why?
| | Larynx | 1 | 2020 | 47 | 0.180 |
Why?
| | Survival Rate | 3 | 2019 | 1644 | 0.170 |
Why?
| | Radiosurgery | 1 | 2022 | 299 | 0.170 |
Why?
| | Reoperation | 2 | 2018 | 514 | 0.160 |
Why?
| | Papillomavirus Infections | 1 | 2022 | 261 | 0.160 |
Why?
| | Tracheal Neoplasms | 1 | 2019 | 11 | 0.160 |
Why?
| | Lymph Nodes | 2 | 2019 | 419 | 0.160 |
Why?
| | Pharyngectomy | 1 | 2018 | 2 | 0.160 |
Why?
| | Medicare | 2 | 2020 | 665 | 0.160 |
Why?
| | Mouth Neoplasms | 1 | 2019 | 70 | 0.150 |
Why?
| | Oropharyngeal Neoplasms | 1 | 2018 | 38 | 0.150 |
Why?
| | Nomograms | 1 | 2018 | 41 | 0.150 |
Why?
| | Canada | 1 | 2018 | 322 | 0.140 |
Why?
| | Carcinoma, Adenosquamous | 1 | 2017 | 9 | 0.140 |
Why?
| | Health Services Needs and Demand | 1 | 2019 | 243 | 0.140 |
Why?
| | Carcinoma, Mucoepidermoid | 1 | 2017 | 15 | 0.140 |
Why?
| | Surgical Flaps | 1 | 2018 | 121 | 0.140 |
Why?
| | Parotid Diseases | 1 | 2017 | 4 | 0.140 |
Why?
| | Paranasal Sinus Neoplasms | 1 | 2017 | 17 | 0.140 |
Why?
| | Carcinoma, Adenoid Cystic | 1 | 2017 | 17 | 0.140 |
Why?
| | Nose Neoplasms | 1 | 2017 | 15 | 0.140 |
Why?
| | Microvessels | 1 | 2017 | 68 | 0.140 |
Why?
| | Parotid Neoplasms | 1 | 2017 | 14 | 0.140 |
Why?
| | Induction Chemotherapy | 1 | 2017 | 56 | 0.140 |
Why?
| | Vocal Cord Dysfunction | 1 | 2016 | 7 | 0.130 |
Why?
| | Humans | 20 | 2023 | 114662 | 0.130 |
Why?
| | Fellowships and Scholarships | 1 | 2018 | 227 | 0.130 |
Why?
| | Tomography, Optical Coherence | 1 | 2016 | 130 | 0.120 |
Why?
| | Postoperative Complications | 3 | 2023 | 2128 | 0.120 |
Why?
| | Evidence-Based Medicine | 1 | 2018 | 668 | 0.120 |
Why?
| | Recurrence | 1 | 2017 | 935 | 0.120 |
Why?
| | Female | 11 | 2019 | 59493 | 0.110 |
Why?
| | Male | 12 | 2022 | 55583 | 0.110 |
Why?
| | Middle Aged | 9 | 2020 | 26733 | 0.110 |
Why?
| | Aged | 10 | 2020 | 19069 | 0.110 |
Why?
| | Ultrasonography | 1 | 2017 | 634 | 0.110 |
Why?
| | United States | 5 | 2020 | 12181 | 0.100 |
Why?
| | Disease-Free Survival | 3 | 2020 | 620 | 0.100 |
Why?
| | Adult | 8 | 2022 | 30544 | 0.100 |
Why?
| | Melanoma | 1 | 2017 | 620 | 0.090 |
Why?
| | Retrospective Studies | 7 | 2023 | 12546 | 0.090 |
Why?
| | Neoplasm Staging | 3 | 2019 | 1167 | 0.090 |
Why?
| | Magnetic Resonance Imaging | 2 | 2017 | 3046 | 0.080 |
Why?
| | Databases, Factual | 3 | 2019 | 1125 | 0.080 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2016 | 1355 | 0.080 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2013 | 663 | 0.080 |
Why?
| | Cross-Sectional Studies | 1 | 2018 | 4408 | 0.080 |
Why?
| | Neoadjuvant Therapy | 2 | 2022 | 304 | 0.080 |
Why?
| | Time Factors | 1 | 2017 | 6115 | 0.070 |
Why?
| | Anion Transport Proteins | 1 | 2006 | 8 | 0.070 |
Why?
| | Surveys and Questionnaires | 1 | 2018 | 4622 | 0.070 |
Why?
| | Directed Molecular Evolution | 1 | 2006 | 21 | 0.070 |
Why?
| | Radiotherapy, Adjuvant | 2 | 2017 | 182 | 0.070 |
Why?
| | Chemotherapy, Adjuvant | 2 | 2017 | 332 | 0.060 |
Why?
| | Alphapapillomavirus | 2 | 2018 | 36 | 0.060 |
Why?
| | Prognosis | 3 | 2019 | 3329 | 0.060 |
Why?
| | Combined Modality Therapy | 2 | 2019 | 1121 | 0.060 |
Why?
| | Survival Analysis | 2 | 2019 | 1211 | 0.060 |
Why?
| | Proportional Hazards Models | 2 | 2017 | 1075 | 0.060 |
Why?
| | Multivariate Analysis | 2 | 2017 | 1430 | 0.050 |
Why?
| | Evolution, Molecular | 1 | 2006 | 430 | 0.050 |
Why?
| | Anastomosis, Surgical | 1 | 2023 | 136 | 0.050 |
Why?
| | Optic Nerve | 1 | 2022 | 65 | 0.050 |
Why?
| | Injections | 1 | 2022 | 159 | 0.050 |
Why?
| | Heparin | 1 | 2023 | 224 | 0.050 |
Why?
| | Tissue Plasminogen Activator | 1 | 2023 | 225 | 0.050 |
Why?
| | Fibrinolytic Agents | 1 | 2023 | 234 | 0.040 |
Why?
| | Fluorodeoxyglucose F18 | 1 | 2020 | 113 | 0.040 |
Why?
| | Positron-Emission Tomography | 1 | 2020 | 259 | 0.040 |
Why?
| | Hypopharynx | 1 | 2018 | 1 | 0.040 |
Why?
| | Anticoagulants | 1 | 2023 | 550 | 0.040 |
Why?
| | Operative Time | 1 | 2018 | 106 | 0.040 |
Why?
| | Critical Care | 1 | 2022 | 476 | 0.040 |
Why?
| | Preoperative Period | 1 | 2018 | 103 | 0.040 |
Why?
| | Aged, 80 and over | 2 | 2019 | 6345 | 0.040 |
Why?
| | Postoperative Period | 1 | 2018 | 289 | 0.040 |
Why?
| | National Cancer Institute (U.S.) | 1 | 2017 | 40 | 0.040 |
Why?
| | Chemoradiotherapy, Adjuvant | 1 | 2017 | 40 | 0.040 |
Why?
| | Otorhinolaryngologic Surgical Procedures | 1 | 2017 | 33 | 0.030 |
Why?
| | Biopsy, Fine-Needle | 1 | 2017 | 64 | 0.030 |
Why?
| | Office Visits | 1 | 2017 | 79 | 0.030 |
Why?
| | Vocal Cords | 1 | 2016 | 25 | 0.030 |
Why?
| | Propensity Score | 1 | 2017 | 224 | 0.030 |
Why?
| | Chemoradiotherapy | 1 | 2017 | 188 | 0.030 |
Why?
| | Neoplasm Invasiveness | 1 | 2017 | 442 | 0.030 |
Why?
| | Cisplatin | 1 | 2016 | 262 | 0.030 |
Why?
| | Healthcare Disparities | 1 | 2020 | 480 | 0.030 |
Why?
| | Laryngoscopy | 1 | 2016 | 91 | 0.030 |
Why?
| | Epithelial Cells | 1 | 2020 | 950 | 0.030 |
Why?
| | Socioeconomic Factors | 1 | 2019 | 1078 | 0.030 |
Why?
| | Kaplan-Meier Estimate | 1 | 2017 | 811 | 0.030 |
Why?
| | Program Evaluation | 1 | 2018 | 822 | 0.030 |
Why?
| | Treatment Outcome | 2 | 2018 | 9088 | 0.030 |
Why?
| | Analysis of Variance | 1 | 2017 | 1226 | 0.030 |
Why?
| | Length of Stay | 1 | 2018 | 962 | 0.030 |
Why?
| | Receptor, Notch2 | 1 | 2013 | 14 | 0.030 |
Why?
| | Gonanes | 1 | 2013 | 27 | 0.030 |
Why?
| | Receptor, Notch1 | 1 | 2013 | 59 | 0.030 |
Why?
| | Cetuximab | 1 | 2013 | 90 | 0.030 |
Why?
| | Phosphatidylinositol 3-Kinases | 1 | 2013 | 329 | 0.020 |
Why?
| | Quality Improvement | 1 | 2018 | 950 | 0.020 |
Why?
| | Xenograft Model Antitumor Assays | 1 | 2013 | 698 | 0.020 |
Why?
| | Blotting, Western | 1 | 2013 | 1147 | 0.020 |
Why?
| | Follow-Up Studies | 1 | 2019 | 4411 | 0.020 |
Why?
| | ErbB Receptors | 1 | 2013 | 554 | 0.020 |
Why?
| | Computational Biology | 1 | 2013 | 530 | 0.020 |
Why?
| | Immunohistochemistry | 1 | 2013 | 1629 | 0.020 |
Why?
| | Risk Assessment | 1 | 2017 | 2968 | 0.020 |
Why?
| | Tomography, X-Ray Computed | 1 | 2017 | 2285 | 0.020 |
Why?
| | Cohort Studies | 1 | 2017 | 4895 | 0.020 |
Why?
| | Renilla | 1 | 2006 | 2 | 0.020 |
Why?
| | Organic Anion Transporters | 1 | 2006 | 15 | 0.020 |
Why?
| | Gerbillinae | 1 | 2006 | 61 | 0.020 |
Why?
| | Infant, Newborn | 1 | 2017 | 5045 | 0.020 |
Why?
| | Protein Interaction Mapping | 1 | 2006 | 101 | 0.020 |
Why?
| | Protein Structure, Secondary | 1 | 2006 | 325 | 0.020 |
Why?
| | Risk Factors | 1 | 2019 | 8632 | 0.020 |
Why?
| | Structure-Activity Relationship | 1 | 2006 | 502 | 0.020 |
Why?
| | Infant | 1 | 2017 | 7961 | 0.010 |
Why?
| | Child, Preschool | 1 | 2017 | 9114 | 0.010 |
Why?
| | Amino Acid Sequence | 1 | 2006 | 1982 | 0.010 |
Why?
| | Molecular Sequence Data | 1 | 2006 | 2785 | 0.010 |
Why?
| | Young Adult | 1 | 2017 | 10466 | 0.010 |
Why?
| | Cell Line | 1 | 2006 | 2636 | 0.010 |
Why?
| | Animals | 2 | 2013 | 31699 | 0.010 |
Why?
| | Adolescent | 1 | 2017 | 17841 | 0.010 |
Why?
| | Child | 1 | 2017 | 18412 | 0.010 |
Why?
| | Mice | 1 | 2013 | 14863 | 0.010 |
Why?
|
|
Goddard's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|